TP53 and myelodysplastic syndrome: Additionally, Azacitidine in combination with Magrolimab (anti-CD47 antibody) and APR-246 (Eprenetapopt) are exploited in high-risk MDS patients including those with TP53 mutations, which have a complete remission rate lower than 20% with the standard-of-care Azacitidine therapy and poor prognosis.